AU2017259436B2 - Piperidines as menin inhibitors - Google Patents
Piperidines as menin inhibitors Download PDFInfo
- Publication number
- AU2017259436B2 AU2017259436B2 AU2017259436A AU2017259436A AU2017259436B2 AU 2017259436 B2 AU2017259436 B2 AU 2017259436B2 AU 2017259436 A AU2017259436 A AU 2017259436A AU 2017259436 A AU2017259436 A AU 2017259436A AU 2017259436 B2 AU2017259436 B2 AU 2017259436B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- alkyl
- methyl
- optionally substituted
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330350P | 2016-05-02 | 2016-05-02 | |
| US62/330,350 | 2016-05-02 | ||
| PCT/US2017/030577 WO2017192543A1 (en) | 2016-05-02 | 2017-05-02 | Piperidines as menin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017259436A1 AU2017259436A1 (en) | 2018-12-20 |
| AU2017259436B2 true AU2017259436B2 (en) | 2021-08-26 |
Family
ID=58699299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017259436A Ceased AU2017259436B2 (en) | 2016-05-02 | 2017-05-02 | Piperidines as menin inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10899738B2 (enExample) |
| EP (1) | EP3452461B1 (enExample) |
| JP (1) | JP6991585B2 (enExample) |
| KR (1) | KR20190015275A (enExample) |
| CN (1) | CN109415337B (enExample) |
| AU (1) | AU2017259436B2 (enExample) |
| BR (1) | BR112018072570A2 (enExample) |
| CA (1) | CA3022868A1 (enExample) |
| ES (1) | ES2899936T3 (enExample) |
| IL (2) | IL262697B (enExample) |
| MX (1) | MX384087B (enExample) |
| SG (1) | SG11201809714TA (enExample) |
| WO (1) | WO2017192543A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10246464B2 (en) | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| KR102419524B1 (ko) | 2016-03-16 | 2022-07-08 | 쿠라 온콜로지, 인크. | 메닌-mll의 가교된 이환식 억제제 및 사용 방법 |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| US10899738B2 (en) | 2016-05-02 | 2021-01-26 | The Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| ES2872003T3 (es) | 2016-09-14 | 2021-11-02 | Janssen Pharmaceutica Nv | Inhibidores espirobicíclicos de la interacción de menina-MLL |
| CN109715634B (zh) | 2016-09-14 | 2022-09-27 | 詹森药业有限公司 | Menin-mll相互作用的稠合二环抑制剂 |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| KR102513564B1 (ko) | 2016-12-15 | 2023-03-22 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 아제판 억제제 |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| KR20190133224A (ko) * | 2017-03-31 | 2019-12-02 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 공유 메닌 억제제로서의 피페리딘 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| TW202003465A (zh) * | 2018-03-30 | 2020-01-16 | 美國密西根州立大學 | 作為共價menin抑制劑之六氫吡啶化合物 |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| WO2020069027A1 (en) * | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| JP2022502409A (ja) * | 2018-10-03 | 2022-01-11 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | 低分子メニン阻害剤 |
| AU2019417833B2 (en) * | 2018-12-31 | 2024-11-07 | Biomea Fusion, Inc. | Irreversible inhibitors of menin-MLL interaction |
| EP3906029A4 (en) | 2018-12-31 | 2022-09-21 | Biomea Fusion, LLC | MENIN-MLL INTERACTION INHIBITORS |
| TW202126636A (zh) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物 |
| MX2022007652A (es) | 2019-12-19 | 2022-09-23 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal. |
| TW202204334A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| TW202204333A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| MX2023013174A (es) | 2021-05-08 | 2023-11-30 | Janssen Pharmaceutica Nv | Derivados espiro sustituidos. |
| JP2024518425A (ja) | 2021-05-08 | 2024-05-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換スピロ誘導体 |
| KR20240006625A (ko) * | 2021-05-12 | 2024-01-15 | 신닥스 파마슈티컬스, 인크. | 암 치료를 위한 조합물 |
| AU2022286467A1 (en) | 2021-06-01 | 2024-01-25 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES |
| BR112023025436A2 (pt) | 2021-06-03 | 2024-02-27 | Janssen Pharmaceutica Nv | Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas |
| JP2024525145A (ja) | 2021-06-17 | 2024-07-10 | ヤンセン ファーマシューティカ エヌ．ベー． | がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩 |
| JP2024531170A (ja) | 2021-08-11 | 2024-08-29 | バイオメア フュージョン，インコーポレイテッド | 真性糖尿病に対するメニン－ｍｌｌ相互作用の共有結合性阻害剤 |
| JP2024534014A (ja) | 2021-08-20 | 2024-09-18 | バイオメア フュージョン，インコーポレイテッド | 癌の処置のための不可逆的メニン－ＭＬＬ阻害剤、Ｎ－［４－［４－（４－モルホリニル）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－イル］フェニル］－４－［［３（Ｒ）－［（１－オキソ－２－プロペン－１－イル）アミノ］－１－ピペリジニル］メチル］－２－ピリジンカルボキサミドの結晶形態 |
| WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
| EP4525873A1 (en) * | 2022-05-17 | 2025-03-26 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| TW202430528A (zh) | 2023-01-18 | 2024-08-01 | 美商拜歐米富士恩股份有限公司 | Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑 |
| CN120987784A (zh) * | 2025-10-23 | 2025-11-21 | 辽宁鸿港化工有限公司 | 一种对甲氧基苄胺及其制备方法和用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| AU7450898A (en) | 1997-05-28 | 1998-12-30 | Tokyo Tanabe Company Limited | Indole compounds |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| WO2008070303A2 (en) | 2006-10-19 | 2008-06-12 | The University Of Chicago | Therapeutics to inhibit mll-menin interaction for treating leukemia |
| CA2773131C (en) | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| US8946197B2 (en) | 2009-11-16 | 2015-02-03 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| IN2013MN02014A (enExample) | 2011-05-09 | 2015-06-12 | Forma Tm Llc | |
| BR112015022602A2 (pt) | 2013-03-13 | 2017-07-18 | Univ Michigan Regents | composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos |
| US9212180B2 (en) * | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
| WO2014200479A1 (en) | 2013-06-12 | 2014-12-18 | The Regents Of The University Of Michigan | Menin-mll inhibitors and methods of use thereof |
| US10246464B2 (en) | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| RU2018126774A (ru) | 2015-12-22 | 2020-01-23 | Витэ Фармасьютикалз, Инк. | Ингибиторы менин-mll взаимодействия |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| KR102419524B1 (ko) | 2016-03-16 | 2022-07-08 | 쿠라 온콜로지, 인크. | 메닌-mll의 가교된 이환식 억제제 및 사용 방법 |
| US10899738B2 (en) | 2016-05-02 | 2021-01-26 | The Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| KR20190133224A (ko) | 2017-03-31 | 2019-12-02 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 공유 메닌 억제제로서의 피페리딘 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| WO2020069027A1 (en) | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
-
2017
- 2017-05-02 US US16/098,147 patent/US10899738B2/en not_active Expired - Fee Related
- 2017-05-02 CA CA3022868A patent/CA3022868A1/en not_active Abandoned
- 2017-05-02 MX MX2018013433A patent/MX384087B/es unknown
- 2017-05-02 ES ES17722968T patent/ES2899936T3/es active Active
- 2017-05-02 KR KR1020187034933A patent/KR20190015275A/ko not_active Ceased
- 2017-05-02 AU AU2017259436A patent/AU2017259436B2/en not_active Ceased
- 2017-05-02 EP EP17722968.9A patent/EP3452461B1/en active Active
- 2017-05-02 WO PCT/US2017/030577 patent/WO2017192543A1/en not_active Ceased
- 2017-05-02 JP JP2018557418A patent/JP6991585B2/ja not_active Expired - Fee Related
- 2017-05-02 SG SG11201809714TA patent/SG11201809714TA/en unknown
- 2017-05-02 CN CN201780040586.6A patent/CN109415337B/zh not_active Expired - Fee Related
- 2017-05-02 BR BR112018072570A patent/BR112018072570A2/pt not_active IP Right Cessation
-
2018
- 2018-10-31 IL IL262697A patent/IL262697B/en active IP Right Grant
-
2020
- 2020-11-23 US US17/101,323 patent/US20210198237A1/en not_active Abandoned
-
2021
- 2021-03-02 IL IL281182A patent/IL281182A/en unknown
Non-Patent Citations (1)
| Title |
|---|
| HE S. ET AL., "High-affinity small molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction", JOURNAL OF MEDICINAL CHEMISTRY, (2014-01-28), vol. 57, pages 1543 - 1556 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190152947A1 (en) | 2019-05-23 |
| US20210198237A1 (en) | 2021-07-01 |
| ES2899936T3 (es) | 2022-03-15 |
| IL262697A (en) | 2018-12-31 |
| EP3452461B1 (en) | 2021-09-08 |
| JP6991585B2 (ja) | 2022-01-12 |
| MX384087B (es) | 2025-03-14 |
| MX2018013433A (es) | 2019-07-18 |
| KR20190015275A (ko) | 2019-02-13 |
| US10899738B2 (en) | 2021-01-26 |
| CN109415337B (zh) | 2022-01-18 |
| JP2019514950A (ja) | 2019-06-06 |
| IL281182A (en) | 2021-04-29 |
| CA3022868A1 (en) | 2017-11-09 |
| IL262697B (en) | 2021-04-29 |
| AU2017259436A1 (en) | 2018-12-20 |
| EP3452461A1 (en) | 2019-03-13 |
| CN109415337A (zh) | 2019-03-01 |
| WO2017192543A1 (en) | 2017-11-09 |
| SG11201809714TA (en) | 2018-11-29 |
| BR112018072570A2 (pt) | 2019-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017259436B2 (en) | Piperidines as menin inhibitors | |
| AU2017246452B2 (en) | MDM2 protein degraders | |
| CA2785340C (en) | Substituted isoquinolinones and quinazolinones | |
| AU2018269947B2 (en) | Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors | |
| CA3104131A1 (en) | Inhibitors of cyclin-dependent kinases | |
| AU2014249192A1 (en) | BET bromodomain inhibitors and therapeutic methods using the same | |
| CA3058448A1 (en) | Piperidines as covalent menin inhibitors | |
| BR112016016158B1 (pt) | Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos | |
| BR112013000275B1 (pt) | derivados de tetraidro-pirido-pirimidina, seus usos, combinação e composição farmacêuticas | |
| MX2012004997A (es) | Derivados de imidazol como inhibidores de la caseina quinasa. | |
| CA3093454A1 (en) | Piperidine compounds as covalent menin inhibitors | |
| CA2863132A1 (en) | Isoquinoline and naphthyridine derivatives | |
| JP2023515095A (ja) | 置換アリール系化合物 | |
| TW202204333A (zh) | Menin抑制劑及治療癌症之使用方法 | |
| CA3112340A1 (en) | Small molecule menin inhibitors | |
| WO2018109271A1 (en) | New bromodomain inhibitors | |
| HK40006016B (en) | Piperidines as menin inhibitors | |
| HK40006016A (en) | Piperidines as menin inhibitors | |
| WO2025245351A1 (en) | Substituted aryl sulfonamides and compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |